Norges Bank has acquired a significant new position in McDonald's Corporation, purchasing 9.46 million shares valued at approximately $2.89 billion. This investment gives Norges Bank about 1.33% ownership in McDonald's, following the fast-food giant's strong Q4 earnings, which surpassed analyst expectations in both EPS and revenue. McDonald's also declared a quarterly dividend of $1.86 per share and maintains a consensus "Moderate Buy" rating from analysts.

Zweig DiMenna Associates LLC significantly reduced its stake in Loar Holdings Inc. by 31.9% in the fourth quarter, yet still holds 158,246 shares valued at $10.76 million. The article notes strong insider buying activity, with directors recently purchasing shares, contributing to a total of $11.33 million in insider buys over the past 90 days. Despite the institutional reduction, Loar Holdings reported better-than-expected Q1 results and maintains a "Moderate Buy" analyst rating with an average price target of $83.

Zacks Research has downgraded Li Auto (NASDAQ:LI) from "hold" to "strong sell," reflecting a cautious outlook for the company. This downgrade, combined with recent disappointing earnings and conservative guidance, has led to Li Auto receiving an average "Reduce" rating with a consensus price target of $17.55. The stock's performance has been weak, trading near its 52-week low and below key moving averages, as analysts monitor for a reacceleration of demand for its hybrid vehicles.

Cardinal Health Inc. shares are trading around USD 200 on the NYSE, with a market capitalization in the mid-$40 billion range. The company, a key player in the U.S. healthcare logistics market, has seen significant insider selling over the past two years, totaling over 420,000 shares worth approximately USD 56.8 million. This activity, alongside its operational performance and market dynamics, keeps the stock in focus for investors.

This article focuses on Abbott Laboratories (US0028241000) and its continued active listing on the NYSE as of May 30, 2026. The main point of interest is the company's ownership structure and director dealings, despite the absence of new insider filings for the specified date. Investors are advised to monitor SEC filings like Form 4 or 13D/13G for any potential changes in insider or block-holder positions.

Triodos Investment Management BV reduced its stake in eBay by 11.9% in the fourth quarter, selling 73,500 shares, but eBay still represents 3.4% of their holdings. While several institutional investors increased their stakes, insider selling has continued, and analysts generally rate eBay as a "Hold." Despite mixed sentiment, eBay reported stronger-than-expected Q1 earnings with EPS of $1.66 and revenue of $3.09 billion, and has declared a quarterly dividend of $0.31 per share.

Incyte's Monjuvi, when used in a multi-drug regimen including chemotherapy for aggressive non-Hodgkin lymphoma, significantly reduced the risk of disease progression, relapse, or death by 25% compared to standard treatment alone. However, this benefit came with a higher rate of severe side effects and patient discontinuations due to adverse events. The company plans to seek expanded approval for this combination as an initial treatment for newly diagnosed patients, potentially doubling the eligible patient population.

This article provides a weekly market update, covering topics such as the performance of AI stocks, the bond market's reaction to rising yields, and potential governance risks for prospective SpaceX IPO investors. It highlights Morningstar's analysis of stocks with significant fair value estimate changes and offers a screen for undervalued AI stocks. The piece also delves into the competitive landscape between Anthropic and OpenAI and discusses the anticipated SpaceX IPO.

Molecular Partners (NASDAQ: MOLN) announced that its DLL3-targeting radio-DARPin MP0712 is now dosing patients in a US Phase 1/2a trial for small cell lung cancer and other neuroendocrine tumors. The company will present trial-in-progress posters at ASCO 2026 and SNMMI 2026, with initial clinical data expected in 2026. This therapy relies on the high expression of DLL3 in over 85% of SCLC tumors and leverages a diagnostic isotope, 203Pb, for early imaging and dosimetry data, supporting its continued clinical development.

WASHINGTON TRUST Co has acquired a new stake of 102,598 shares, valued at $19.03 million, in Marsh & McLennan Companies during the fourth quarter. This move highlights continued strong institutional interest in the financial services provider, with 87.99% of the stock owned by hedge funds and other institutions. The company recently reported Q1 earnings of $3.29 per share, exceeding estimates, and analysts currently rate the stock a "Hold" with an average price target of $203.56.